Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA® (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Disease Burden

Core Insights - The KINECT-PRO analysis is the first and only study to report both remission of tardive dyskinesia symptoms and improvements in patient-reported outcomes [1] - Post-hoc analysis from KINECT-PRO showed substantial symptomatic remission rates at Week 24, occurring earlier than in previous studies [1]